John Stock to Humans
This is a "connection" page, showing publications John Stock has written about Humans.
Connection Strength
0.084
-
Stock JL, Mershon JL, Schoenfeld MJ. Review of comparative effectiveness of treatments to prevent fractures. Ann Intern Med. 2008 Jun 03; 148(11):885; author reply 887.
Score: 0.012
-
Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007 Apr; 40(4):843-51.
Score: 0.010
-
Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin. 2005 Dec; 21(12):1955-9.
Score: 0.010
-
Adachi JD, Adami S, Kulkarni PM, Wong M, Stock JL. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. J Clin Densitom. 2005; 8(3):273-7.
Score: 0.009
-
Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. J Fam Pract. 2004 Oct; 53(10):789-96.
Score: 0.009
-
Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002 Feb; 23(1):16-37.
Score: 0.007
-
Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013 Mar 23; 13:15.
Score: 0.004
-
Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011 Feb; 26(2):397-404.
Score: 0.003
-
Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Effect of Raloxifene on all-cause mortality. Am J Med. 2010 May; 123(5):469.e1-7.
Score: 0.003
-
Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008 Jan; 23(1):112-20.
Score: 0.003
-
Meadows ES, Stock J, Johnston JA. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies. Med Decis Making. 2006 Nov-Dec; 26(6):633-5; author reply 636-7.
Score: 0.003
-
Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005 Sep; 20(9):1514-24.
Score: 0.002
-
Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc. 2004 Sep; 52(9):1543-8.
Score: 0.002
-
Lufkin EG, Sarkar S, Kulkarni PM, Ciaccia AV, Siddhanti S, Stock J, Plouffe L. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin. 2004 Mar; 20(3):351-7.
Score: 0.002
-
Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002 Jan; 17(1):1-10.
Score: 0.002
-
El-Hajj Fuleihan G, Stock JL, McClung MR, Saifi G. A national random survey of bone mineral density reporting in the United States. J Clin Densitom. 2002; 5(1):3-9.
Score: 0.002